FGF-3 Amplification in Ovarian Cancer
Author Information
Author(s): A. Rosen, P. Sevelda, M. Klein, K. Dobianer, C. Hruza, K. Czerwenka, H. Hanak, N. Vavra, H. Salzer, S. Leodolter, M. Medls, J. Spona
Primary Institution: University of Vienna
Hypothesis
Is there an association between FGF-3 copy numbers and established prognostic factors in ovarian cancer?
Conclusion
FGF-3 amplification may indicate the aggressiveness of ovarian cancer but does not correlate with overall survival.
Supporting Evidence
- 80% of the tumor samples showed single copy FGF-3 oncogene.
- 20% of ovarian tumors had an amplified FGF-3 gene.
- Preoperative CA 125 levels were above the cut-off in 82.6% of patients.
Takeaway
This study looked at a gene called FGF-3 in women with ovarian cancer to see if it could help predict how aggressive the cancer is. They found that more copies of this gene might mean a more aggressive cancer.
Methodology
Quantitative PCR was used to estimate FGF-3 oncogene amplification in DNA samples from 136 ovarian cancer patients.
Limitations
The study had a small sample size and did not find a correlation between FGF-3 amplification and overall survival.
Participant Demographics
Median age of participants was 61 years, with a range from 27 to 88 years.
Statistical Information
P-Value
0.008
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website